BB Liquidatin a Aktie

BB Liquidatin a für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 924821 / ISIN: US0936791088

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
18.08.2024 20:10:00

Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived

Over the last couple of years, the pharmaceutical industry has been taken over by glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with that terminology, I'd wager that you're well aware of diabetes and obesity medications such as Ozempic, Wegovy, and Mounjaro -- which are all GLP-1 drugs.For now, Denmark-based Novo Nordisk (NYSE: NVO) dominates the GLP-1 market, thanks to its deep roster of treatments including Ozempic, Wegovy, Rybelsus, and Saxenda. However, Novo Nordisk's chief rival in the weight loss space shouldn't be slept on.Eli Lilly (NYSE: LLY), the developer of Mounjaro, has proven that it can compete with Novo Nordisk at a high level. Moreover, the company's sibling treatment to Mounjaro -- Zepbound -- has gotten off to a sizzling start since its approval last November to aid weight loss. With more than $1.2 billion in sales in the three months ended in June, Zepbound has already gained the "blockbuster drug" status given to medications selling more than $1 billion in a year.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu BB Liquidating Inc. (A)mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!